title: Effect of Oral Lipid Matrix Supplement on Fat Absorption in Cystic Fibrosis: A Randomized Placebo-Controlled Trial.
abstract: Pancreatic enzyme therapy does not normalize dietary fat absorption in patients with cystic fibrosis and pancreatic insufficiency. Efficacy of LYM-X-SORB (LXS), an easily absorbable lipid matrix that enhances fat absorption, was evaluated in a 12-month randomized, double-blinded, placebo-controlled trial with plasma fatty acids (FA) and coefficient of fat absorption (CFA) outcomes. A total of 110 subjects (age 10.4 ± 3.0 years) were randomized. Total FA increased with LXS at 3 and 12 months (+1.58, +1.14 mmol/L) and not with placebo (P = 0.046). With LXS, linoleic acid (LA) increased at 3 and 12 months (+298, +175 nmol/mL, P ≤ 0.046), with a 6% increase in CFA (P < 0.01). LA increase was significant in LXS versus placebo (445 vs 42 nmol/mL, P = 0.038). Increased FA and LA predicted increased body mass index Z scores. In summary, the LXS treatment improved dietary fat absorption compared with placebo as indicated by plasma FA and LA and was associated with better growth status.
authors.affiliation: *Division of Gastroenterology, Hepatology and Nutrition, The Children's Hospital of Philadelphia †Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia ‡Community Health Sciences, University of Calgary, Calgary, Alberta, Canada §Stockton University, Pomona, NJ ||Center for Adherence and Self-Management, Cincinnati Children's Hospital Medical Center ¶Department of Pediatrics, Division of Behavioral Medicine and Clinical Psychology, University of Cincinnati College of Medicine, Cincinnati, OH #Westat Biostatistics and Data Management Core, Children's Hospital of Philadelphia, Philadelphia, PA **Avanti Polar Lipids, Inc, Alabaster, AL.
authors.forename: Virginia A
authors.initials: VA
authors.lastname: Stallings
authors.forename: Joan I
authors.initials: JI
authors.lastname: Schall
authors.forename: Asim
authors.initials: A
authors.lastname: Maqbool
authors.forename: Maria R
authors.initials: MR
authors.lastname: Mascarenhas
authors.forename: Belal N
authors.initials: BN
authors.lastname: Alshaikh
authors.forename: Kelly A
authors.initials: KA
authors.lastname: Dougherty
authors.forename: Kevin
authors.initials: K
authors.lastname: Hommel
authors.forename: Jamie
authors.initials: J
authors.lastname: Ryan
authors.forename: Okan U
authors.initials: OU
authors.lastname: Elci
authors.forename: Walter A
authors.initials: WA
authors.lastname: Shaw
mesh_terms: D000293:Adolescent; D002648:Child; D002664:Child Nutritional Physiological Phenomena; D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D004041:Dietary Fats / Q000378:metabolism*; D010188:Exocrine Pancreatic Insufficiency / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology; D005260:Female; D006801:Humans; D007408:Intestinal Absorption; D019787:Linoleic Acid / Q000627:therapeutic use; D008055:Lipids / Q000627:therapeutic use*; D008297:Male; D016896:Treatment Outcome
chemical_list: D004041:Dietary Fats; D008055:Lipids; D019787:Linoleic Acid